Midostaurin (7) is a multikinase inhibitor and is effective primarily during the induction and consolidation phase of AML treatment in combination with chemotherapy, while Gilteritinib, a FLT3ITD inhibitor, with activity against other kinases such as AXL, was approved for refractory and relapsed patients with AML (8). This evidence concerns the gene AXL and acute myeloid leukemia.